Asymptomatic breakthrough: Participants who seroconverted to possess anti-N IgG/IgA antibodies between 2 and 6 weeks and 6 months post-second dose without ever displaying COVID-19-related symptoms or testing positive by PCR/RAT. This evidence concerns the gene CD79A and COVID-19.